Background The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50. In this study, we evaluated the efficacy and safety of the combined therapy with terazosin (α1-adrenergic receptor antagonist) and tolterodine (anticholinergic agent) for LUTS associated with BPH. Methods This combination study included 69 patients diagnosed with LUTS associated with BPH based on the International Prostate Symptom Scores (IPSS), urinary flow rate, prostate volume, urinary residual, and their serum prostate-specific antigen levels. Initially, 191 patients were treated with terazosin 2 mg once daily for one week. Those patients with continued LUTS after the initial treatment were allocated randomly into two groups: terazosin group (n=36) in which patients were treated with terazosin 2 mg once daily for six weeks, and combination group (n=33) in which patients were treated with both terazosin 2 mg once daily and tolterodine 2 mg twice daily for 6 weeks. Results The IPSS were significantly improved in both groups after treatment, and the reduction of IPSS in the combination group was significantly greater than that in the terazosin group (P<0.01). A decrease in urgency, frequency and nocturia were the main contributory factors causing the reduction of IPSS in the combination group. The differences about the peak urinary flow rate and the residual urine from the baseline values were noted in both groups after treatment, but were not significant between the two groups. The incidence of adverse effects in the combination group was higher than that in the terazosin group. As expected the most common adverse effect was mouth dryness which was associated with anticholinergic drugs such as tolterodine. Conclusions Patients with LUTS associated BPH appear the improved IPSS after combined therapy with terazosin and tolterodine. This study, although short term and limited numbers of patients, provides evidence that the combined therapy with terazosin plus tolterodine is a good approach for meeting the objectives of rapid, sustained, and safe improvements in the LUTS associated with BPH. And the profile of patients in this study might be used as the indication of such combined therapy for LUTS associated with BPH without urodynamic evaluation.
enign prostatic hyperplasia (BPH) is a common disease experienced by most men over 50 years. The lower urinary tract symptoms (LUTS) associated with BPH start to occur at that age and the number of men with these symptoms increases with age, approximately 50% in eighties have LUTS associated with BPH. The symptoms of LUTS include urgency, frequency, nocturia, a weak and intermittent urinary stream, and difficulty in initiating urination. 1 However, its cause in 47% of men over 50 years is not bladder outlet obstruction (BOO), but rather changes of bladder function, 2,3 especially urgency, frequency and nocturia. These symptoms, the main reasons for patients with LUTS associated with BPH seek medical help, 4,5 significantly affect the patients' quality of life.
In clinical practice, α-adrenergic receptor antagonists or 5α-reductase inhibitors are commonly used to treat LUTS associated with BPH. The literatures indicated that a 25% improvement or more is achieved in 66% of patients treated with tamsulosin, an α1-adrenergic receptor antagonist 6 and the improvement was found in one third to one half of the patients treated with finasteride, a 5α-reductase inhibitor. 7 These data indicate that although the treatment with either an α1-adrenergic receptor antagonist or a 5α-reductase inhibitor provides some improvement, many patients with LUTS associated with BPH still suffer from the symptoms affecting their quality of life. Although some researchers have examined the combined use of α1-adrenergic receptor antagonist and 5α-reductase inhibitor, and found some improvement over the single drugs, none has looked at the combined therapy with the α1-adrenergic receptor antagonist (terazosin) and anticholinergic drug (tolterodine). In this study, we evaluated the efficacy and safety of the combined therapy with terazosin and tolterodine in patients with LUTS associated with BPH.
METHODS

Patients
From March 2005 to January 2006, 191 patients with LUTS suspected of being resulted from BPH were screened in the Out-patient Department of Beijing Chaoyang hospital. The International Prostate Symptom Scores (IPSS), 8 transrectal ultrasound (TRUS) for prostate size, 9 and uroflowmetry were evaluated and assayed. The amount of the residual urine was measured by bladderScan 6100 10 immediately after the uroflow rate measuring. The protocol of this study was approved by the Ethical Committee of the Beijing Chaoyang Hospital, Affiliate of Capital University of Medical Sciences, and all patients signed the written consents before inclusion.
Exclusive criteria
Patients were excluded from this study according to the following criteria: a peak urinary flow rate (Q max ) less than 10 ml/s, residual urine over 50 ml, the prostate volume over 50 ml, a history of urinary tract infections, serum prostate-specific antigen over 4 ng/ml, 11 any other bladder diseases or drug treatment impacting the bladder function and causing LUTS. Patients with the contraindications of using α1-adrenergic receptor antagonist or anticholinergic agent were also excluded.
Grouping
After treatment with terazosin at a dose of 2 mg once daily for one week, 69 patients (36.1%, 69/191) were still experiencing bothersome lower urinary tract symptoms including urinary frequency, urgency, urinary incontinence, and then were enrolled in the final study. They were randomly allocated to either the terazosin therapy group or the combination therapy group for additional six weeks. The random method was that odd numbers of patients' serial number were allocated into terazosin group and even numbers were allocated into the combination group.
Treatment and examination
The thirty-six patients in the terazosin group continued to receive terazosin 2 mg once daily, and the 33 patients in the combination group received terazosin 2 mg once daily plus tolterodine 2 mg twice daily, both were treated for additional six weeks. The patients were re-examined at week 2, 4, and 6 to determine their IPSS, analyze their urinary flow rate, and document any adverse effects. At week 6 (the end-point), the IPSS, the uroflow rate, the prostate volume, residual urine, urine analysis, biochemical tests (liver and renal functions), and the adverse effects were examined for all patients. The residual urine was determined before treatment and at week 6 immediately after the uroflow rate was measured. The prostate volume was calculated from the ellipsoid volume. 11
Statistical analysis
The measurement data were expressed as mean ± standard deviation (SD) and analyzed by the two-side Student's t test. The numerical variables were analyzed by χ 2 test using SPSS 12.0. P value less than 0.05 was considered statistically significant.
RESULTS
Baseline characteristics
The baseline characteristics of all the 69 patients in the two groups are shown in Table 1 . No significant baseline differences (age, body weight, prostate volume, IPSS, Q max , and residual urine) were noted between the two groups. 
Therapeutic efficacy
The changes from baseline in the two groups after treatment with terazosin or the combination of terazosin plus tolterodine for 6 weeks are shown in Comparison of the therapeutic effect between the two groups after 6-week treatment showed that the 5.1 reduction of the total IPSS and 4 reduction of the storage IPSS in the combination group were significantly greater than the 1.2 reduction and 1 reduction in the terazosin group, respectively (both P<0.01); however, there were no significant differences in the voiding IPSS, Q max , and residual urine between the two groups after 6-week treatment ( Table 2) .
Assessment of safety
One patient in the terazosin group had dyspepsia, the total incidence of adverse effects in this group was 2.8% (1/36). In the combination group, three patients had mouth dryness and one of them also complained of abdominal fullness, one experienced dizziness, one complained of eye dryness, and one had mild increased intraocular pressure; the total incidence of individuals experiencing adverse effects in this group was 18.2% (6/33), which was higher as compared to that in the terazosin group (P< 0.05). None of the patients had liver or renal dysfunction before or after treatment.
DISCUSSION
LUTS associated with BPH should be managed by watchful waiting 12, 13 or medical therapy with 5α-reductase inhibitor, 14 α1-adrenergic receptor antagonist, the combination of these two drugs, 15 or surgery. Using α1-adrenergic receptor antagonists has been the preferred initial treatment for LUTS associated with BPH since Caine et al 16 showed the effectiveness of these agents for treating LUTS associated with BPH 30 years ago. In the past 10 years, many large-scale, well-designed, randomized, placebo-controlled trials have provided the evidences for the efficacy and safety of α1-adrenergic receptor antagonists for treating LUTS associated with BPH. It is currently believed that α1-adrenergic receptor antagonists improve uroflow rate and voiding symptoms, such as a weak and intermittent urinary stream and difficulty in initiating urination, by blocking α1-adenoceptors in the prostate, urethra, and bladder neck. These medicines can also reduce the symptoms, such as urgency, frequency, and nocturia, by blocking α 1D -adenoceptors.
The data from the Medical Therapy of Prostate Symptoms (MTOPS) Trial showed that the combined therapy with finasteride, a 5α-reductase inhibitor, and doxazosin, an α1-adrenergic receptor antagonist, provided a greater long-term improvement of LUTS associated with BPH symptoms than finasteride or doxazosin individually. 15 However, our clinical experience shows that the individual drugs (finasteride, doxazosin) or the combination does not completely relieve the symptoms especially those related to urgency, frequency, nocturia, or urge incontinence. Instability of the detrusor is considered a common cause of LUTS and has been associated with many causal factors such as aging, concomitant neurological diseases, and BOO. LUTS can become progressively worse with the increasing age of men. 17 Anticholinergic agents have been shown to be very effective for treating the symptoms of an overactive bladder 18 which might occur in patients with LUTS associated with BPH. However, anticholinergic agents are not usually prescribed for this disease because of the worry that these medicines might increase the voiding problems and the risk of urinary retention. We decided to test the combined therapy with an α1-adrenergic receptor antagonist and an anticholinergic agent in LUTS associated with BPH patients since recent studies on the combined therapy with doxazosin or tamsulosin (both α1-adrenergic receptor antagonists) plus tolterodine have indicated the promising results. These studies specifically examined patients with BOO and found the risk of deteriorating voiding symptoms or increased urinary retention. 19, 20 Patients in these two studies were evaluated with urodynamics which could exclude those with severe BOO or impaired detrusor contractility before the clinical trials, even though acute urinary retention occurred in a few cases. 20 As is known, it is not practical to evaluate every patient with urodynamics if the patient just receives medical treatment. 21 In our study, the initial 191 patients with LUTS associated with BPH were screened and treated with terazosin for one week, only 69 patients still experiencing bothersome LUTS which mainly were urinary frequency, urgency, and/or urge incontinence were included into the study. We believe that even without the urodynamic evaluation, these patients screened by our criteria would be in the lowest risk of acute urinary retention if they were treated with anticholinergic agents. The reason we use terazosin in the study is that the drug is the most effective α1 receptor blocker for BPH patients with BOO and also the cheapest α1 receptor blocker in China.
Patients enrolled into this study had relatively small prostate volumes, mildly or moderately impaired bladder voiding functions, residual urine under 50 ml, and the symptoms were not relieved by treatment with only an α1-adrenergic receptor antagonist. The baseline IPSS based on questions 1, 2, 4, and 7 (storage IPSS) were also in the moderate range. We used these inclusive criteria to evaluate the efficacy and safety of the combined therapy for patients with LUTS associated with BPH, and to learn more about the mechanism of this combined therapy.
Our results indicated that the patients fitting the inclusive and exclusive criteria of this study benefited from the combined therapy with terazosin and tolterodine, which proved to both efficacious and relatively safe. This study did not score the quality of life of the patients because of the high expectations of our patients to the treatment and the poor understanding to the meaning of quality of life. After six-week treatment, all patients in the two groups had statistically significant improvements in their IPSS and Q max . In order to better understand the underlying reasons for the efficacy of the combined treatments, we examined the sub-scores of IPSS (storage issues based on questions 1, 2, 4, and 7 and voiding issues based on questions 3, 5, and 6). Analysis of the sub-scores of IPSS in terazosin group indicated that the storage IPSS was reduced by 1, but the voiding score without change. Some factors could have influenced the voiding IPSS, for example, the capacity of the bladder or the subjective responses of the patients. The reductions in the IPSS and storage IPSS in this group were much less than those in the combination group. Therefore, use of only the α1-adrenergic receptor antagonist was not as effective for the LUTS associated BPH patients as the combination treatment. In the combination therapy group, the IPSS was significantly reduced by 4 and the voiding IPSS was significantly decreased by 1.1; this may be related to an increased bladder capacity due to the treatment with an anticholinergic agent. These results indicate that the combined therapy produce a greater improvement in the IPSS than terazosin alone and the profile of these patients in the study might be the indication of such combined therapy for LUTS associated with BPH. We also found that the anticholinergic agent tolterodine even improved the patients' bladder voiding functions for patients fitting the study inclusive criteria.
The total number of patients noting adverse effects in combination group was higher (6/33) than that in terazosin group (1/36). Some of the adverse effects noted in the combination group were mouth dryness (a common anticholinergic effect), abdominal fullness, dizziness, eye dryness, and mild increased intraocular pressure. No significant changes were noted about the residual urine, liver and renal function, or the other baseline vital signs that were measured in the two groups.
The primary objectives of the medical treatment for LUTS/BPH are to produce rapid, sustained, and safe improvements in the lower urinary tract symptoms associated with benign prostatic hyperplasia that affect the quality of life in the majority of men over the age of 50. Although this study is short term and limited in the number of patients, it provides evidence that the combined therapy of an α1-adrenergic receptor antagonist, terazosin, plus an anticholinergic agent, tolterodine, is a good approach for meeting these objectives. And the profile of patients included the study might be used as indication of such combined therapy for patients with LUTS/BPH without urodynamic evaluation. Additional studies on a greater number of patients for longer period are needed to substantiate the preliminary evidence of this study that the combined therapy of an α1-adrenergic receptor antagonist plus an anticholinergic agent provide greater relief from the symptoms associated with LUTS/BPH than an α1-adrenergic receptor antagonist alone.
